Home
report store
renal cancer pipeline insight

Renal Cancer - Pipeline Insight, 2026

Published Date : 2026

Pages : 180

Region : Global,

Summary
TOC Table of Content
LOT
Companies
- Sample Request

Renal Cancer Pipeline

DelveInsight’s, “Renal Cancer Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Renal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Renal Cancer Understanding

Renal Cancer Overview

Renal cancer, also known as kidney cancer, is a malignant disease that originates in the tissues of the kidneys vital organs responsible for filtering blood, removing waste, and maintaining fluid balance. The most common subtype is Renal cell carcinoma, which accounts for the majority of adult cases. Less frequent forms include Urothelial carcinoma of the renal pelvis, Wilms tumor in children, and rare renal sarcomas. The disease is often asymptomatic in its early stages and is increasingly identified incidentally during imaging performed for unrelated medical evaluations.

In its early course, renal cancer may present with subtle or no symptoms, but as it progresses, patients can experience hematuria (blood in the urine), persistent flank or lower back pain, and sometimes a palpable abdominal mass. Systemic manifestations such as unexplained weight loss, fatigue, and intermittent fever may also occur. In advanced stages, symptoms related to metastasis such as bone pain or chronic cough can arise, reflecting disease spread. Features like fever or night sweats without an infectious cause may indicate more advanced or aggressive disease progression.

Renal cancer is frequently detected incidentally during imaging studies such as ultrasound, CT scans, or MRI performed for unrelated conditions. Once a suspicious renal mass is identified, contrast-enhanced CT or MRI is typically used to evaluate tumor size, location, and extent of spread. Additional tests, including urinalysis and blood investigations, help assess kidney function and identify abnormalities. In select cases particularly when imaging findings are unclear or metastasis is suspected, a biopsy may be performed to confirm the diagnosis. This comprehensive approach ensures accurate staging and guides subsequent management decisions.

Management of renal cancer depends on disease stage, tumor characteristics, and patient health. For localized disease, especially Renal cell carcinoma, surgical removal via partial or radical nephrectomy remains the standard of care. In advanced or metastatic settings, systemic therapies such as targeted agents (e.g., tyrosine kinase inhibitors) and immunotherapies (including immune checkpoint inhibitors) are widely used. Active surveillance may be appropriate for small, slow-growing tumors in selected patients. Although radiation therapy is not commonly used for primary tumors, it can provide symptomatic relief in metastatic cases. Treatment strategies are increasingly personalized based on tumor biology and patient-specific factors.

"Renal Cancer Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Renal Cancer pipeline landscape is provided which includes the disease overview and Renal Cancer treatment guidelines. The assessment part of the report embraces, in depth Renal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Renal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Renal Cancer pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Renal Cancer Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Renal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Renal Cancer.

Renal Cancer Emerging Drugs Analysis

This segment of the Renal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Renal Cancer Emerging Drugs

Zanzalintinib: Exelixis

Zanzalintinib (XL092) is an investigational, next-generation oral tyrosine kinase inhibitor being developed by Exelixis for the treatment of renal cell carcinoma (RCC). It targets multiple kinases including VEGFR, MET, and TAM family receptors (AXL, MER), thereby inhibiting tumor angiogenesis, metastasis, and immune evasion. In RCC, zanzalintinib is designed to modulate the tumor microenvironment and enhance responsiveness to immunotherapy. It is being evaluated in combination with agents such as Nivolumab in ongoing clinical trials, including Phase III studies in non-clear cell RCC.

Quavonlimab: Merck

Quavonlimab in combination with Pembrolizumab is an investigational fixed-dose monoclonal antibody regimen being evaluated for the treatment of renal cell carcinoma (RCC) under the LITESPARK-012 study. Quavonlimab targets CTLA-4, enhancing T-cell activation by blocking inhibitory signaling, while pembrolizumab inhibits the PD-1 pathway to restore anti-tumor immune responses. This dual checkpoint blockade is designed to produce a more robust and sustained immune-mediated attack on tumor cells. The combination aims to improve clinical outcomes, particularly in patients with advanced or treatment-resistant RCC. Quavonlimab is being developed under an agreement with Akeso Inc. and is currently under Phase III of its development.

Ciforadenant: Corvus Pharmaceuticals

Ciforadenant is an oral, small-molecule antagonist of the adenosine A2A receptor, designed to counteract adenosine-mediated immunosuppression within the tumor microenvironment. By blocking A2A signaling, it enhances the activity of cytotoxic T cells and promotes anti-tumor immune responses. In renal cell carcinoma (RCC), where high adenosine levels contribute to immune evasion, ciforadenant has shown potential to restore immune sensitivity. It is being investigated both as a monotherapy and in combination with immune checkpoint inhibitors, particularly in patients resistant to prior immunotherapies. According to the company’s pipeline, Ciforadenant is currently in Phase II development for Renal Cancer.

Darlifarnib: Kura Oncology

Darlifarnib (KO-2806) is an investigational, next-generation farnesyl transferase inhibitor (FTI) being evaluated for the treatment of renal cell carcinoma (RCC). In combination with Cabozantinib, a multi-kinase inhibitor targeting VEGFR, MET, and AXL pathways, darlifarnib aims to enhance anti-tumor efficacy by simultaneously disrupting oncogenic signaling and tumor angiogenesis. This combination approach is designed to overcome resistance mechanisms commonly observed with monotherapies in advanced RCC. By targeting complementary pathways, the regimen may provide deeper and more durable clinical responses. The drug is currently in Phase I development for the treatment of Renal cell carcinoma (RCC).

BMS-986506: Bristol-Myers Squibb

BMS-986506 is an investigational small-molecule therapy being developed by Bristol Myers Squibb for the treatment of advanced renal cell carcinoma (RCC). It is currently being evaluated in a first-in-human Phase I/Ib clinical trial in patients with advanced or metastatic RCC who have progressed on prior therapies. The study focuses on assessing its safety, tolerability, and pharmacokinetic profile as a monotherapy. BMS-986506 remains investigational, and its safety and efficacy are yet to be established. The drug is currently being evaluated in Phase I for the treatment of Renal cell carcinoma (RCC).

ATG-106: Antengene Corporation

ATG-106 is an investigational bispecific antibody designed to target CDH6 on tumor cells and CD3 on T cells, enabling direct T-cell–mediated killing of cancer cells. By binding CDH6, which is overexpressed in certain ovarian cancers and renal cell carcinoma (kidney cancer), the therapy selectively directs immune activity toward malignant cells. Simultaneous engagement of CD3 activates T cells, promoting cytotoxic responses within the tumor microenvironment. This mechanism aims to enhance anti-tumor efficacy while minimizing off-target effects. The drug is currently in preclinical stage of its development for the treatment of Renal Cancer.

DR315: Zhejiang Doer Biologics

DR315 is an investigational bispecific antibody drug conjugate (ADC) designed for the treatment of clear cell renal cell carcinoma (RCC). It targets both CA9 and CD70, leveraging their differential expression on tumor versus normal tissues to enhance tumor selectivity and reduce on-target toxicity, particularly hematological effects seen with CD70-directed therapies. DR315 incorporates a novel linker with a topoisomerase inhibitor payload, enabling efficient delivery of cytotoxic activity directly to cancer cells. In preclinical in vitro and in vivo studies, it has demonstrated strong tumor cell killing and anti-tumor efficacy, along with a favorable safety profile in non-human primate studies. DR315 remains investigational, with plans to submit an IND application in 2026.

Further product details are provided in the report……..

Renal Cancer Drug Therapeutic Assessment

This segment of the report provides insights about the different Renal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Renal Cancer Players in Renal Cancer

There are approx. 75+ key companies which are developing the therapies for Renal Cancer. The companies which have their Renal Cancer drug candidates in the most advanced stage, i.e. Phase III include, Exelixis.

Renal Cancer Clinical Trial Phases

DelveInsight’s report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Renal Cancer Drug Route of Administration

Renal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Renal Cancer Product Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Renal Cancer Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Renal Cancer Clinical Trial Activities

The Renal Cancer Pipeline report provides insights into different Renal Cancer Clinical Trials within Phase III, II, I, preclinical and discovery stage. It also analyses Renal Cancer therapeutic drugs key players involved in developing key drugs.